952182-44-4

Basic information

• Product Name: 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid
• Synonyms: 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid
• CAS NO: 952182-44-4
• Molecular Formula: C₁₀H₆Cl₂N₂O₂S
• Molecular Weight: 289.14
• Mol File: 952182-44-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 289～291℃
• Appearance: /
• CAS DataBase Reference: 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid(952182-44-4)
• EPA Substance Registry System: 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid(952182-44-4)

Safety Data

• Hazardous Substances Data: 952182-44-4(Hazardous Substances Data)

Usage

Chemical structure

2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid is composed of a thiazole ring and an anilino group that is substituted with two chlorine atoms at the 3 and 4 positions.

Biological significance

It has antimicrobial and anticancer properties and has been studied for its potential use in the treatment of various bacterial infections and as a potential anticancer agent.

Pharmaceutical significance

It is an analog of the antibacterial drug ciprofloxacin, which makes it an important subject of research for the development of new drugs and pharmaceuticals.

Chemical properties

As a carboxylic acid, it has acidic properties and can form salts with bases.

Physical properties

The specific physical properties of 2-(3,4-dichloroanilino)-1,3-thiazole-4-carboxylic acid are not provided in the material, so it is not possible to give accurate information about its physical properties.

Potential applications

It has been studied for its potential use in the treatment of various bacterial infections and as a potential anticancer agent, which suggests that it could have a wide range of medical applications in the future.

Upstream product

• 95-76-1 m,p-dichloroaniline 
• 1113-59-3 bromopyruvic acid 
• 19250-09-0 3,4-dichlorophenylthiourea 

Relevant articles and documents

Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein

Antiviral drug resistance in influenza infections has been a major threat to public health. To develop a broad-spectrum inhibitor of influenza to combat the problem of drug resistance, we previously identified the highly conserved E339?R416 salt bridge of the nucleoprotein trimer as a target and compound 1 as an inhibitor disrupting the salt bridge with an EC50 = 2.7 μM against influenza A (A/WSN/1933). We have further modified this compound via a structure-based approach and performed antiviral activity screening to identify compounds 29 and 30 with EC50 values of 110 and 120 nM, respectively, and without measurable host cell cytotoxicity. Compared to the clinically used neuraminidase inhibitors, these two compounds showed better activity profiles against drug-resistant influenza A strains, as well as influenza B, and improved survival of influenza-infected mice.

SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS

The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.